Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Setipiprant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 19/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 6/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Setipiprant SCHEMBL3089969 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| Setipiprant SCHEMBL29355657 | 1.00 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3089983 | 0.89 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3083833 | 0.89 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3083273 | 0.89 | PTGDR2 (0.80) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3091135 | 0.89 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3081699 | 0.86 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3079230 | 0.85 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3085508 | 0.85 | PTGDR2 (0.73) | PTGDR2PTGDRPTGER2CYP2C9 | |
| SCHEMBL3083537 | 0.84 | PTGDR2 (0.73) | PTGDR2PTGDRPTGER2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250381192-A1 | Treatment of Autoimmune Disease | JAK SLAVE PTY LTD (AU) | 2025-12-18 | — | — | US | claimed |
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| US-12364696-B2 | Treatment of autoimmune disease | JAK SLAVE PTY LTD (AU) | 2025-07-22 | — | — | US | claimed |
| US-20250228844-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-17 | — | — | US | claimed |
| US-12201625-B2 | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-01-21 | — | — | US | claimed |
| WO-2024192765-A1 | FIRST IN CLASS USE OF THE CRTH2 ANTAGONIST IN TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) AND RELEVANT AUTOIMMUNE CNS DISORDERS | BROWN UNIVERSITY (US) | 2024-09-26 | — | — | WO | claimed |
| US-12091708-B2 | Compositions and methods targeting the Th2 pathway for the treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-09-17 | — | — | US | claimed |
| US-20240240208-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF PRECISE EDITING REPAIR | NEW YORK GENOME CENTER INC (US) | 2024-07-18 | — | — | US | claimed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| WO-2024091572-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | VERADERMICS INCORPORATED (US) | 2024-05-02 | — | — | WO | claimed |
| EP-4347815-A2 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF PRECISE EDITING REPAIR | New York Genome Center, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| EP-3328500-B1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 ANTAGONISTS | UNIV PENNSYLVANIA (US) | 2023-04-12 | — | — | EP | claimed |
| US-11541120-B2 | Phosphonium-based ionic drug conjugates | ANTHOS PARTNERS, LP (US) | 2023-01-03 | — | — | US | claimed |
| WO-2022251836-A2 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF PRECISE EDITING REPAIR | NEW YORK GENOME CENTER, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| US-20220187316-A1 | Postural Orthostatic Tachycardia Syndrome and CRTH2 | AMERIMMUNE DIAGNOSTICS LLC | 2022-06-16 | — | — | US | claimed |
| US-20220143025-A1 | TREATMENT OF AUTOIMMUNE DISEASE | JAK SLAVE PTY LTD (AU) | 2022-05-12 | — | — | US | claimed |
| EP-3941579-A1 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND CRTH2 | Amerimmune, LLC (US) | 2022-01-26 | — | — | EP | claimed |
| US-20260144790-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | VERADERMICS, INCORPORATED (US) | 2026-05-28 | — | — | US | disclosed |
| EP-3941579-A1 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND CRTH2 | Amerimmune, LLC (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364696-B2 | Treatment of autoimmune disease | JAK1, JAK3, JAK2 | PTGDR2 2062/4885PTGDR 2795/4885PTGER2 2436/4885 |
| US-20250381192-A1 | Treatment of Autoimmune Disease | JAK1, JAK3, JAK2 | PTGDR2 2062/4885PTGDR 2795/4885PTGER2 2436/4885 |
| US-20250228844-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | PTGDR2, PTGS2, HPGDS | PTGDR2 1/4885PTGDR 6/4885PTGER2 5/4885 |
| US-20220143025-A1 | TREATMENT OF AUTOIMMUNE DISEASE | JAK1, JAK3, JAK2 | PTGDR2 2062/4885PTGDR 2795/4885PTGER2 2436/4885 |
| US-12201625-B2 | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 | PTGDR2, PTGS2, HPGDS | PTGDR2 1/4885PTGDR 6/4885PTGER2 5/4885 |
| US-20260144790-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | SLC6A12, SLC8B1, MC1R | PTGDR2 2229/4885PTGDR 1816/4885PTGER2 1467/4885 |
| US-11541120-B2 | Phosphonium-based ionic drug conjugates | SLC8B1, PHOSPHO1, PBDC1 | PTGDR2 4319/4885PTGDR 4354/4885PTGER2 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.